Arizona Cancer Center Gets Bristol-Myers Squibb Grant

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 3
Volume 7
Issue 3

TUCSON--The Arizona Cancer Center has received a 5-year, $500,000 Bristol-Myers Squibb Unrestricted Cancer Research Grant. Sydney E. Salmon, MD, Regents Professor of Medicine and director of the center, will serve as the grant administrator. Dr. Salmon announced the new funding at a ceremony held to dedicate the center’s $22.5 million expansion project adding 30 new cancer research laboratories to the center.

TUCSON--The Arizona Cancer Center has received a 5-year, $500,000 Bristol-Myers Squibb Unrestricted Cancer Research Grant. Sydney E. Salmon, MD, Regents Professor of Medicine and director of the center, will serve as the grant administrator. Dr. Salmon announced the new funding at a ceremony held to dedicate the center’s $22.5 million expansion project adding 30 new cancer research laboratories to the center.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content